Auto-populated list of related Clinical Trials
(Breast, Cleft Lip and Palate, Hand, Lymphedema, Oral, Skin, Trauma)

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

This is an open-label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and nivolumab in combination with radiotherapy (RT) in 18 subjects with unresectable stage IV melanoma. All subjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses, followed by nivolumab monotherapy (240 mg) every 2 weeks. Radiotherapy will be initiated after the first dose and before the second dose of immunotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborator: Bristol-Myers Squibb

Stanford Investigator(s):

Intervention(s):

  • Drug: Ipilimumab
  • Drug: Nivolumab
  • Radiation: Radiotherapy

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can
   be safely irradiated in the opinion of the radiation oncologist (note: subjects with
   primary ocular and mucosal melanoma are permitted). Lesions may include, but are not
   limited to:

      - Symptomatic lymphadenopathy

      - Bothersome cutaneous disease

      - Hepatic metastases

      - Pulmonary metastases

   2. Excluding the lesion intended to undergo radiation, subjects must have at least 1
   unresectable, non-bony lesion that is measurable radio-graphically (based on RECIST
   1.1).

   3. Any number of prior therapies (including none). For subjects who have received prior
   systemic treatment with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
   Programmed death 1 (PD-1) and/or Programmed death-ligand 1 (PD-L1) therapy, the last
   monoclonal antibody administration should be no less than 6 weeks prior to start of
   this protocol therapy and all prior side effects must have resolved to grade 1 or less
   by the time of the start of this protocol therapy.

   4. Subjects must have completed chemotherapy, targeted therapy, investigational therapy,
   other immunotherapy, prior radiotherapy, or major surgery (requiring general
   anesthesia) at least 28 days before administration of the first dose of study drug(s).
   Subjects undergoing minor surgical procedures and biopsies that do not require general
   anesthesia may begin receiving study therapy if sufficiently recovered as determined
   by the treating investigator. Clinically significant toxicity experienced during any
   prior therapy must be resolved or stabilized before the first dose of study drug(s).

   5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   6. Life expectancy ≥ 4 months.

   7. Screening laboratory parameters:

      - White blood cell count ≥ 2000/μL

      - Absolute neutrophil count ≥ 1500/μL

      - Platelets ≥ 100,000/μL

      - Hemoglobin ≥ 9 g/dL

      - Aspartate aminotransferase and alanine aminotransferase ≤ 3 × upper limit of
      normal

      - Total bilirubin ≤ 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)

      - Serum creatinine ≤ 1.5 x Upper Limit of Normal or creatinine clearance ≥ 40
      mL/min (if using the Cockcroft-Gault formula below):

   Female Creatinine Clearance = [(140 - age in years) x weight in kg x 0.85] / [72 x
   serum creatinine in mg/dL] Male Creatinine Clearance = [(140 - age in years) x weight
   in kg x 1.00] / [72 x serum creatinine in mg/dL]

   8. Age ≥ 18 years.

   9. Able and willing to give valid written informed consent.

Exclusion Criteria:

   1. Any contraindications for ipilimumab (Yervoy®) or nivolumab (Opdivo®) as per the
   package inserts.

   2. Unresolved immune-related adverse events following prior biological therapy. Subjects
   with asymptomatic endocrinopathy may enroll.

   3. Active autoimmune disease or any condition requiring systemic treatment with either
   corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive
   medications within 14 days of study drug administration. Inhaled or topical steroids
   and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in
   the absence of active autoimmune disease.

   4. History of motor neuropathy considered to be of autoimmune origin (e.g.,
   Guillain-Barre Syndrome, Myasthenia Gravis).

   5. Other active, concurrent malignancy that requires ongoing systemic treatment or
   interferes with radiographic assessment of melanoma response as determined by the
   investigator.

   6. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases
   are eligible if metastases have been treated and there is no magnetic resonance
   imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete
   and within 28 days prior to the first dose of nivolumab administration. There must
   also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10
   mg/day prednisone equivalents) for at least 2 weeks prior to study drug
   administration.

   7. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
   Hepatitis B or C without evidence of active infection may be allowed.

   8. History of severe allergic reactions to any unknown allergens or any components of the
   study drugs.

   9. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
   disorders).

10. Requirement of radiotherapy to treat brain metastases or receipt of any non-study
   systemic therapy for cancer or any other experimental/investigational treatment.

11. Mental impairment that may compromise the ability to give informed consent and comply
   with the requirements of the study.

12. Lack of availability for immunological and clinical assessments or post-study
   follow-up contact to determine relapse and survival.

13. Women who are breastfeeding or who are pregnant as evidenced by a positive serum
   pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed
   within 14 days of the first dose of study drug and by a urine pregnancy test (minimum
   sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of
   study drug(s).

14. Females of childbearing potential who are sexually active with a nonsterilized male
   partner must use 2 methods of effective contraception.

15. Any condition that, in the clinical judgment of the treating physician, is likely to
   prevent the subject from complying with any aspect of the protocol or that may put the
   subject at unacceptable risk.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting